UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Tiotropium + olodaterol shows clinically meaningful improvements in quality of life

Respiratory medicine, 2015-10, Vol.109 (10), p.1312-1319

2015

Link zum Volltext

Verfügbarkeit prüfen

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease

Pulmonary pharmacology & therapeutics, 2015-06, Vol.32, p.53-59

2015

Link zum Volltext

Verfügbarkeit prüfen

Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial

Respiratory research, 2020-07, Vol.21 (1), p.1-177, Article 177

2020

Link zum Volltext

Verfügbarkeit prüfen

β-Blockers in COPD: A Cohort Study From the TONADO Research Program

Chest, 2018-06, Vol.153 (6), p.1315-1325

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies

Respiratory research, 2016-06, Vol.17 (1), p.73, Article 73

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies

NPJ primary care respiratory medicine, 2017-02, Vol.27 (1), p.7-9, Article 7

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO ® and OTEMTO ® studies: a subgroup analysis by age

International journal of chronic obstructive pulmonary disease, 2016, Vol.11 (1), p.2701-2710

2016

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease

Respiratory investigation, 2017-03, Vol.55 (2), p.121-129

2017

Link zum Volltext

Verfügbarkeit prüfen

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)

The European respiratory journal, 2015-04, Vol.45 (4), p.969-979

2015

Link zum Volltext

Verfügbarkeit prüfen

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial

The lancet respiratory medicine, 2018-05, Vol.6 (5), p.337-344

2018

Link zum Volltext

Verfügbarkeit prüfen

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies

International journal of chronic obstructive pulmonary disease, 2016-01, Vol.11 (1), p.2017-2027

2016

Link zum Volltext

Verfügbarkeit prüfen

Effects of baseline symptom burden on treatment response in COPD

International journal of chronic obstructive pulmonary disease, 2019-01, Vol.14, p.181-194

2019

Link zum Volltext

Verfügbarkeit prüfen

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)

International journal of chronic obstructive pulmonary disease, 2016-02, Vol.11, p.193-205

2016

Link zum Volltext

Verfügbarkeit prüfen

The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study)

International journal of chronic obstructive pulmonary disease, 2016, Vol.11, p.193-205

2016

Link zum Volltext

Verfügbarkeit prüfen

β-Blockers in COPD

Chest, 2018-06, Vol.153 (6), p.1315-1325

2018

Link zum Volltext

Verfügbarkeit prüfen

Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease

Advances in therapy, 2017-07, Vol.34 (7), p.1622-1635

2017

Link zum Volltext

Verfügbarkeit prüfen

Author’s reply

International journal of chronic obstructive pulmonary disease, 2016-11, Vol.11 (1), p.2910

2016

Link zum Volltext

Verfügbarkeit prüfen

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and luticasone propionate via Accuhaler® (ENERGITO® study)

International journal of chronic obstructive pulmonary disease, 2016-02, p.193

2016

Link zum Volltext

Verfügbarkeit prüfen

A Short Protocol for Methacholine Provocation Testing Adapted to the Rosenthal-Chai Dosimeter Technique

Chest, 1997-04, Vol.111 (4), p.866-869

1997

Link zum Volltext

Verfügbarkeit prüfen

Author correction. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)

The European respiratory journal, 2015-06, Vol.45 (6), p.1763-1763

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of azelastine, montelukast, and their combination on allergen-induced bronchoconstriction in asthma

Pulmonary pharmacology & therapeutics, 2008-01, Vol.21 (1), p.61-66

2008

Link zum Volltext

Verfügbarkeit prüfen

Author's reply

International journal of chronic obstructive pulmonary disease, 2016-01, Vol.11 (1), p.2910

2016

Link zum Volltext

Verfügbarkeit prüfen

Author's reply

International journal of chronic obstructive pulmonary disease, 2016-01, Vol.11 (1), p.2910

2016

Link zum Volltext

Verfügbarkeit prüfen

The lung function profile of once-daily tiotropium and olodaterol via Respimat[R] is superior to that of twice-daily salmeterol and futicasone propionate via Accuhaler[R] (ENERGITO[R] study).(ORIGINAL RESEARCH)

International journal of chronic obstructive pulmonary disease, 2016-01, Vol.11 (1), p.193

2016

Link zum Volltext

Verfügbarkeit prüfen

Author's reply

International journal of chronic obstructive pulmonary disease, 2016-01, Vol.11 (1), p.2910

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(15)
Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Male
(14)
Middle Aged
(13)
Aged
(12)
Female
(12)
Pulmonary Disease, Chronic Obstructive - Drug Therapy
(12)
Respiratory System
(12)
Double-Blind Method
(11)
Treatment Outcome
(9)
Administration, Inhalation
(8)
Benzoxazines - Administration & Dosage
(8)
Chronic Obstructive Pulmonary Disease
(8)
Clinical Medicine
(8)
Copd
(8)
Pulmonary Disease, Chronic Obstructive - Physiopathology
(8)
Tiotropium
(8)
Tiotropium Bromide - Administration & Dosage
(8)
Asthma
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tiotropium + olodaterol shows clinically meaningful improvements in quality of life

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease

Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial

β-Blockers in COPD: A Cohort Study From the TONADO Research Program

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies

Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO ® and OTEMTO ® studies: a subgroup analysis by age

Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies

Effects of baseline symptom burden on treatment response in COPD

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)

The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study)

β-Blockers in COPD

Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease

Author’s reply

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and luticasone propionate via Accuhaler® (ENERGITO® study)

A Short Protocol for Methacholine Provocation Testing Adapted to the Rosenthal-Chai Dosimeter Technique

Author correction. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)

Effect of azelastine, montelukast, and their combination on allergen-induced bronchoconstriction in asthma

Author's reply

Author's reply

The lung function profile of once-daily tiotropium and olodaterol via Respimat[R] is superior to that of twice-daily salmeterol and futicasone propionate via Accuhaler[R] (ENERGITO[R] study).(ORIGINAL RESEARCH)

Author's reply

Suchergebnisse filtern